Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco and Co-Director of the UCSF Clinical Microbiology Laboratory.
Dr. Chiu currently leads a translational research laboratory focused on the development and clinical validation of metagenomic next-generation sequencing (mNGS) and host response profiling assays for diagnosis of infections, outbreak investigation, and pathogen discovery. He is a principal developer of clinical mNGS assays for pathogen detection from cerebrospinal fluid, plasma, and respiratory fluids that have achieved breakthrough device designation from the FDA. Chiu also leverages machine learning-based approaches to develop host response classification models based on RNA gene expression for differential diagnosis of acute infectious syndromes (meningitis / encephalitis and sepsis) and infection-associated chronic illnesses (Lyme disease, chronic fatigue syndrome, and long COVID).
Dr. Chiu has authored more than 200 peer-reviewed publications, holds over 15 patents and patent applications, is a co-founder of Delve Bio, and serves on the scientific advisory boards of Bay Area Lyme Foundation, Delve Bio, Biomeme, Mammoth Biosciences, Flightpath Biosciences, Biomesense, and Poppy Health.
Dr. Chiu is a Bay Area Lyme Foundation grant recipient. He has also received funding from the National Institutes of Health (NIH), US Department of Defense (DoD), Abbott Laboratories, and Chan-Zuckerberg Biohub.
Dr. Chiu is also the co-PI of the UCSF Lyme Clinical Trials Network (CTN) for Lyme and tick-borne diseases. The Lyme Clinical Trials Center (CTC) at UCSF was funded by a $1m grant from Bay Area Lyme Foundation and is led by Dr. Chiu and Dr. Felicia Chow. As the West Coast ‘node’ in the network, UCSF’s Lyme Clinical Trials Center focuses on interventional trials and diagnostic studies to improve diagnosis and treatment of Lyme disease.